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Abstract
Daptomycin is a lipopeptide antibiotic produced by the soil bacterium Strep-
tomyces roseosporus that is clinically used to treat severe infections with Gram-
positive bacteria. In this review, we discuss the mode of action of this impor-
tant antibiotic. Although daptomycin is structurally related to amphomycin
and similar lipopeptides that inhibit peptidoglycan biosynthesis, experimen-
tal studies have not produced clear evidence that daptomycin shares their
action mechanism. Instead, the best characterized effect of daptomycin is the
permeabilization and depolarization of the bacterial cell membrane. This ac-
tivity, which can account for daptomycin’s bactericidal effect, correlates with
the level of phosphatidylglycerol (PG) in the membrane. Accordingly, reduced
synthesis of PG or its increased conversion to lysyl-PG promotes bacterial re-
sistance to daptomycin. While other resistance mechanisms suggest that dap-
tomycin may indeed directly interfere with cell wall synthesis or cell division,
such effects still await direct experimental confirmation. Daptomycin’s com-
plex structure and biosynthesis have hampered the analysis of its structure
activity relationships. Novel methods of total synthesis, including a recent one
that is carried out entirely on a solid phase, will enable a more thorough and
systematic exploration of the sequence space.
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1. Introduction
Medical science relies heavily on antibiotics for treating bacterial infec-
tions. However, bacterial resistance against many antibiotics that have seen
widespread use has become a major medical issue, and this problem is ex-
pected to become much more serious in the not-to-distant future. Fortunately,
physicians have at their disposable a handful of antibiotics against which
widespread resistance has not yet appeared. These antibiotics are used as
a last defence against serious infections when other antibiotics fail. One of
these so-called last-resort antibiotics is daptomycin (Figure 1).
The activity of daptomycin involves the cytoplasmic membrane; it is cal-
cium-dependent and limited to Gram-positive bacteria, against which it has
been in clinical use since 2003 (see sections 2 and 3). While daptomycin is a
young drug, it quickly became to be widely used in clinical practice; neverthe-
less, bacterial resistance for now remains relatively rare. Nevertheless, cases of
non-susceptibility during daptomycin therapy in clinically important organ-
isms such as Staphylococcus aureus and Enterococcus faecium or E. faecalis are
appearing with increasing frequency.1,2
With several other classes of antibiotics, most notably β-lactams, bacterial
resistance has been countered by structural alterations to the drug molecules,
which has greatly extended their useful lifespans. While such a strategy would
appear worthwhile with daptomycin also, there are several challenges to over-
come in this case. The molecule is larger and more complex than most other
commonly used antibiotics, and the scope of semisynthetic modification is
limited. The molecule is a peptide, but it is non-ribosomally synthesized,
which makes the introduction of structural changes using molecular genet-
ics a non-trivial undertaking (see section 8). Finally, while daptomycin has
been shown to permeabilize bacterial membranes (see section 10.4), its action
mode is still incompletely understood. Despite a large number of experimen-
tal studies, no macromolecular targets have been unambiguously identified,
and neither have the strategic positions within the daptomycin molecule itself
that are responsible for target interaction. Thus, before we can pursue ratio-
nal strategies for modification that would improve daptomycin’s activity and
counter bacterial resistance, we will have to attain a better understanding of
these molecular properties.
The purpose of this review is to present a detailed summary of the studies
that have been performed to elucidate daptomycin’s mode of action. The
best-understood effect is permeabilization of the cytoplasmic membrane,
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which involves the formation of membrane-associated oligomers (see section
10.7). Several studies have reported inhibition of macromolecular biosynthe-
sis, which may occur as a consequence of membrane permeabilization, or
possibly through direct effects of daptomycin on specific macromolecular
targets (see section 11). Aspects such as the history of daptomycin, its clinical
development and use, pharmacokinetics, biosynthesis, bacterial resistance,
as well as related antibiotics will be covered only to the extent required for an
adequate understanding of the main subject. Readers interested in learning
more about these topics are referred to several previous reviews.1–17
2. History
Daptomycin is a member of the A21978C group of calcium-dependent,
cyclic lipopeptide antibiotics that were originally isolated from the fermenta-
tion broth of Streptomyces roseosporus by researchers at Eli Lily in the early
1980s.18,19 These compounds showed excellent activity against a variety of
Gram-positive organisms, but they were inactive against Gram-negatives.
Eli Lily began the clinical development of daptomycin in 1985, but later
abandoned it when they observed myopathic side effects during Phase II tri-
als. In 1997, Cubist Pharmaceuticals Inc. (recently acquired by Merck & Co.)
licensed daptomycin and resumed clinical testing. They found that the myo-
pathic side effects could be minimized by altering the dose regimen.20 These
successful tests resulted in approval for clinical use beginning in 2003 (see next
section).
3. Antimicrobial spectrum and clinical use
Daptomycin was approved for clinical use in the USA in 2003, and in Europe
in 2006, for treating complicated skin and skin-structure infections caused
by methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and
MRSA), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dys-
galactiae subsp. equisimilis, as well as vancomycin-susceptible Enterococcus
faecalis. Furthermore, in 2006, approval was given for treatment of bacter-
aemia and right-sided endocarditis caused by MSSA and MRSA.3 Although
many cyclic lipopeptide antibiotics have been discovered,4,5 daptomycin re-
mains the only member of this class that is approved for clinical use.
A notable gap in the clinical action spectrum of daptomycin is Streptococ-
cus pneumoniae, the leading cause of community-acquired pneumonia. While
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S. pneumoniae is highly susceptible in vitro, this does not translate into suffi-
cient therapeutic activity in vivo. The likely cause for this discrepancy is the
inhibition of daptomycin by lung surfactant, which binds and sequesters the
drug.21 The inhibition may be related to its content of phosphatidylglycerol
(see section 10.1). Efforts have been made to develop daptomycin derivatives
that avoid surfactant inhibition (see section 8.3).
4. Structure and biosynthesis
The structure of daptomycin is shown in Figure 1. Daptomycin and all
other members of the A21978C group of lipopeptides are synthesized by the
same modular non-ribosomal synthetase system22 (see Figure 2) and contain
the same peptide moiety; the only part of the structure that differs between
them is the N-terminally attached fatty acyl residue. The common peptide
moiety contains 13 amino acids, six of which are non-proteinogenic: D-Asn(2),
ornithine (Orn(6)), D-Ala(8), D-Ser(11), (2S,3R)-methylglutamate (MeGlu(12)), and
kynurenine (Kyn(13)). The C-terminal ten amino acids form a macrocyclic core,
which contains a ring-closing depsi (ester) bond between the side chain of
Thr(4) and theα-COOH of the C-terminal Kyn(13).23,24 The N-terminal tripeptide
protrudes from the ring and carries the variable fatty acyl residue, which is
attached to Trp(1).
The nature of the fatty acyl residue affects both antibacterial activity and
toxicity; a decanoyl residue imparts the most favourable combination.26 This
derivative, which became daptomycin (Dap), is only a minor product when
S. roseosporus is fermented in conventional rich media. However, daptomycin
can be produced as a major component by supplementing the fermentation
medium with decanoic acid;27 this observation greatly facilitated its large scale
production, purification and further development.
5. Relationship to other calcium-dependent lipopeptide antibiotics
There are two major groups of calcium-dependent lipopeptides, all of
which are produced by soil bacteria that belong to Streptomyces or related gen-
era.16 The group that contains daptomycin (or rather, the A21978C complex)
also contains the A54145 group (Figure 1), as well as the so-called “calcium-
dependent antibiotic” (CDA). All of these are lipodepsipeptides, because the
core macrocycle is closed by an ester bond. It seems likely that they also share
4
 Figure 1: Structure of daptomycin (Dap) and the related Ca2+-dependent lipopeptide antibi-
otics A54145 Factor D and tsushimycin. In Dap, the non-proteinogenic amino acids are shown
in blue (D-amino acids) and green. The ester bond is highlighted in red. MeGlu: (2S,3R)-
methylglutamate; Kyn: kynurenine, Orn: ornithine; Sar: sarcosine; MeOAsp: methoxyas-
partate; HOAsn: hydroxyasparagine; Pip: pipecolinic acid; Map: β-methylaspartate; Dab:
2,3-diaminobutyric acid.
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Figure 2: Schematic of the modular daptomycin synthetase. Each amino acid is incorporated
by a cognate module that has a C-A-T domain structure and an optional E domain, which
mediate condensation, activation, thiolation, and epimerization, respectively. A: Each amino
acid is first adenylated by the A domain and then attached to the T domain of its cognate mod-
ule. B: The C domain acquires the nascent peptide from the preceding module and attaches
the amino acid to the peptide’s C-terminus through a peptide bond. C: The synthesis of the
daptomycin peptide core is carried out in a sequence by three large enzymes (DptA, DptBC,
and DptD). Each of these enzymes contains multiple amino acid-conferring modules. The
DptF module supplies activated acyl tails to DptA. The thioesterase domain (TE) at the end of
DapD cyclizes and releases the lipopeptide. Adapted from reference 25 with permission.
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the same mechanism of action, although functional studies are scarce for
molecules other than daptomycin.
The second group contains tsushimycin (also shown in Figure 1) as well
as amphomycin, laspartomycin, and several others. In these molecules, the
peptide macrocycle is closed by an amide bond rather than an ester bond.
The members of this group also share one action mechanism, which consists
of binding and sequestering undecaprenol phosphate, a bacterial membrane
constituent that is an essential carrier coenzyme in the assembly and mem-
brane translocation of peptidoglycan precursors. This was shown first for am-
phomycin28,29 and more recently for friulimycin30 and laspartomycin.31
Structural homology is greater within each group, yet it is also considerable
between them (cf. Figure 1). The macrocycles of both groups contain 10 amino
acids. Within this ring, two acidic amino acids—corresponding to Asp(7) and
Asp(9) in daptomycin—are conserved, and both are essential for the activity of
daptomycin (section 8). Furthermore, positions that contain D-amino acids in
one group are either conserved in the other or occupied by glycine and sarco-
sine, which are achiral, so that no incompatible steric constraints are imposed
by the DL-isomerism of the peptide backbone. While the structural similarities
between both groups have prompted researchers to look for a direct, specific
inhibition by daptomycin of peptidoglycan synthesis also, no such effect has
yet been substantiated.32
The similarity between the cyclic lipopeptide antibiotics also pertains to
their synthetase systems. Through genetic recombination of these modular
synthetases, hybrid lipopeptides can be generated.22 One such study explored
a series of hybrids between daptomycin and A54145.33 A54145 is more toxic
than daptomycin, but unlike the latter is not inhibited by lung surfactant.
In initial testing, one particular hybrid compound appeared to combine the
favourable traits of both, although no further confirmatory evidence has since
been reported.
6. Physiochemical Properties
6.1. Ionization state
Daptomycin has six amino acid residues with ionizable side chains: four
acidic residues and two residues containing primary amino groups (see Table
1). The pKa values of these residues in the absence of Ca
2+ have been charac-
terized by potentiometric titration, ultraviolet (UV) spectrophotometry, and
NMR spectroscopy.34,35 At physiological pH, all residues except Kyn(13) will be
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Table 1: Ionizable amino acid residues of daptomycin and their pKa values
Residue pKa
Anionic residues Asp(3) 4.3
Asp(7) 1.0
Asp(9) 3.8
mGlu(12) 4.6
Cationic residues Kyn(13) 0.8-1.3
Orn(6) 10.7
ionized; accordingly, daptomycin with no calcium bound (apo-daptomycin)
exists primarily as a trianion. It may be noted that the pKa value for Asp
(7) is
very low; the exact reason is not clear from the available structural information.
NMR studies carried on daptomycin in solution indicate that Ca2+ binds
to daptomycin in a cooperative manner and with a 1:1 stoichiometry36,37 (see
also section 7.2). Therefore, the Ca2+-bound form of daptomycin in solution
exists as a monoanion.
6.2. Intrinsic fluorescence
Daptomycin contains two fluorophores: Trp(1) and Kyn(13). Since the emis-
sion spectrum of tryptophan overlaps the absorption spectrum of kynurenine,
there is efficient Förster-type energy transfer between them, causing the Trp(1)
residue to have a very low quantum yield.38 The intrinsic fluorescence prop-
erties of daptomycin have been used extensively to probe the interaction of
daptomycin with membranes (see section 10) as well as its aggregation in so-
lution (see the following section).
6.3. Aggregation of free daptomycin in solution
Daptomycin’s amphiphilic structure suggests that it may form aggregates
in solution. This question has been studied with 1H-NMR36,39 and optical
methods.40 In the absence of calcium and at pH 7.4 or higher, daptomycin
aggregation is minimal or absent at millimolar concentrations, whereas under
acidic conditions aggregates may form at concentrations as low as 0.12-0.2
mM. This pH-dependent variation can be explained by the ionization state of
apo-daptomycin. Between pH 2.5 and 4, apo-daptomycin exists primarily as
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a neutral or monoanionic species. As the pH increases to 7, deprotonation of
Asp(3) and mGlu(12) will cause the dianionic and trianionic forms to dominate.
6.4. Calcium-induced aggregation and its role in daptomycin delivery to bac-
terial cells
Of potentially greater interest to the biological activity of daptomycin is
its aggregation in Ca2+-bound form. Ca2+ will shield some of the negative
charges, and one would therefore expect it to promote aggregation, as has
indeed been reported in several studies. Since Ca2+-induced aggregation has
been proposed to mediate the delivery of daptomycin to bacterial membranes,
this topic will be discussed in some detail.
Ball et al. reported that the addition of as little as 0.3 equivalents of Ca2+
to daptomycin at 0.8 mM and pH 5.0 caused significant line broadening in
the 1H-NMR spectrum, indicating the onset of aggregation. Line broadening
increased up to 1 equivalent of Ca2+ and then ceased.36 The change in line
width had a sigmoidal dependence on the amount of Ca2+ added, suggesting
cooperative binding. The addition of Ca2+ did not result in discernible changes
to chemical shifts. Rotondi and Gierasch also noted significant line broadening
in the 1H-NMR spectrum of 1.5 mM daptomycin at pH 5.3 upon addition of
10 mM Ca2+.39
The effect of Ca2+ on daptomycin aggregation has also been studied using
ultracentrifugation.41 With 2.5 mM of daptomycin at pH 7.0, no aggregation
was observed up to 0.75 equivalents of Ca2+. However, micelles consisting of
14 daptomycin monomers formed once a 1:1 ratio of Ca2+ to daptomycin was
reached. When Ca2+ was replaced with Mg2+, 2.5 of the salt equivalents were
required to induce micelle formation.
Based on these experimental observations of Ca2+-induced aggregation in
solution, it has been suggested that daptomycin micelles act as vehicles to de-
liver daptomycin to the bacterial cell membranes in high local concentrations
and in a functional conformation.42 Once in contact with the bacterial mem-
brane, the daptomycin micelle would then dissociate, allowing monomeric
daptomycin to insert into the bilayer.
A similar view has been presented by Qiu et al.,40 who observed the ag-
gregation of native daptomycin by fluorescence at concentrations above 0.06
mM or 100 µg/ml in the presence of 1 mM Ca2+. However, such daptomycin
concentrations still substantially exceed the MICs for clinically susceptible
pathogens; they occur in human plasma only immediately after application of
the drug; and moreover, 90% of the total amount of daptomycin in plasma is
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protein-bound, most likely in monomeric form,43,44 and the unbound remain-
der would remain well below the experimental aggregation threshold.
Fluorescence experiments using micromolar concentrations of two deriva-
tives of daptomycin labelled with Alexa Fluor 350 and 7-nitro-2,1,3-benzoxa-
diazol (NBD-Dap; Figure 3) detected no FRET between both, with or without
Ca2+ present,45 suggesting that aggregation does not occur at concentrations
near the MIC. It cannot be ruled out, however, that the covalently attached
fluorescent labels may have affected the extent of aggregation.
Overall, the micelle delivery mechanism is thus unsupported by relevant
evidence; and considering that formation of large aggregates with multiple
negative charges would hinder rather than facilitate daptomycin’s permeation
through the bacterial cell wall, it also lacks plausibility.
7. Structural studies
Knowing the structure of daptomycin in its various forms—free in solution,
calcium-bound in solution, and bound to both calcium and susceptible target
membranes—would be helpful for elucidating its mechanism of action. Some,
but not all of these structures have been characterized by NMR.
7.1. Solution structure of apo-daptomycin
Three reports have appeared that describe the solution structure of apo-
daptomycin.36,39,42 All three arrive at different structures.
Jung et al. examined a 2 mM solution of daptomycin at pH 6.6.42 As dis-
cussed above in section 6.3, apo-daptomycin should not aggregate under these
conditions. They essentially found no preferred structure. A model of the struc-
ture closest to the ensemble average shows the backbone forming two bends
at Asp(7) and Asp(9), with a highly variable region around Gly(5) (see Figure 4B).
Rotondi and Gierasch used a 1.9 mM solution of apo-daptomycin at pH 5.3
for their NMR studies.39 From the findings described in section 6.3, one would
expect apo-daptomycin to exist mainly as aggregates under these conditions.
However, these workers reported that they avoided aggregation by adding solid
daptomycin to a degassed buffer in successive small portions, each of which
was allowed time to completely dissolve prior to the next addition. The well-
defined and sharp lines of their spectra, better than those in the other two
studies, support this claim. In contrast to Jung et al., Rotondi and Gierasch
did find a preferred aqueous conformation for apo-daptomycin. The cyclic
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Figure 3: Structures and antimicrobial activities of fluorescent derivatives used to study the
interaction of daptomycin with membranes. All labels shown in this figure were attached to
the unique amino group of the Orn(6) side chain.
portion adopted a hairpin-like structure with a type II’ β-turn centred on D-
Ala(8)/Asp(9), and a pseudo-β-turn forming the other end of the hairpin at Kyn-
13/Thr-4. The acyl chain and the hydrophobic Trp(1) and Kyn(13) residues were
clustered at one end of the hairpin, while polar neutral and ionic residues were
situated at the other.
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Figure 4: Crystal structure of tsushimycin, 46 and NMR structure of daptomycin. 42 A: In
tsushimycin, Ca2+ is coordinated by Asp(5) together with several backbone carbonyls from
the ring. Additional calcium ions that bridge adjoining tsushimycin molecules in the crystal
are not shown. B: In daptomycin, the ring has a looser structure, and the side chain carboxyl
groups point away from the ring and from each other. No Ca2+ binding site is obvious. In both
structures, the fatty acyl tails have been omitted.
Ball et al. used a 0.8 mM solution at pH 5.0 for their NMR studies on apo-
daptomycin.36 Some aggregation of apo-daptomycin would be expected to
occur under these conditions. A preferred aqueous conformation for apo-dap-
tomycin was also reported. Their best quality structure indicated an extended
conformation with turns at D-Ala(8) and Gly(10)/D-Ser(11). The backbone amide
groups were oriented inwards, while most of the peptide side-chain groups
protruded outwards from the decapeptide ring and appeared exposed to sol-
vent. The decanoyl residue was flexible with a large degree of conformational
freedom. They suggested that the four acidic residues, Asp(3), Asp(7), Asp(9) and
mGlu(12) are not close enough to each other to render an effective Ca2+ binding
site.
7.2. Solution structure of calcium-bound daptomycin
Two reports have appeared describing the structure of Ca2+-bound dapto-
mycin.36,42 The Hancock group reported the a structure obtained using sam-
ples of 2 mM daptomycin with 5 mM Ca2+ at pH 6.6.42 Under these conditions,
some line broadening was noted, indicating some extent of aggregation. Their
structure of the Ca2+-bound daptomycin was found to be better defined than
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their structure of apo-daptomycin, as several medium and long range Nuclear
Overhauser Effects (NOEs) were observed, whereas only sequential NOEs were
found for apo-daptomycin. In their Ca2+-bound structure, the ring was less
circular, and the side chain of Asp(3) was tucked underneath the ring. They pro-
posed that a Ca2+ binding site might exist between Asp(3) and Asp(7). Moreover,
the side chains were redistributed, and there was an increase in the amount of
hydrophobic surface exposed to solvent. This suggested to them that dapto-
mycin undergoes a significant conformational change upon binding Ca2+.
Rotondi and Gierasch39 as well as Bunkoczi et al.46 pointed out that, since
Straus et al. had used conditions of incipient aggregation, some or all of their
measured medium and long range NOEs might have arisen from intermolec-
ular interactions. Realizing that daptomycin aggregation may have affected
their results, Straus et al. re-examined their Ca2+-bound daptomycin structure
in detail.37 Molecular dynamics (MD) simulations suggested that the confor-
mational change in daptomycin upon binding Ca2+ might not be as significant
as originally proposed. It was concluded that none of the Ca2+-bound dap-
tomycin models tested in the MD simulations were consistent with the NOE
restraints reported earlier, and that the previously reported NOE restraints
between residues Asp(3) and Ala(8) were intermolecular and should not been
included during structure refinement. Overall, these studies led to a revised
structure for Ca2+-bound daptomycin that did not differ significantly from
their previously reported apo-daptomycin structure. This conclusion is con-
sistent with CD measurements, which showed only minor spectral changes
upon addition of Ca2+ to daptomycin in solution.42 No Ca2+ binding site was
obvious in the refined structure. They also determined the structure of dap-
tomycin (2 mM) in the presence of 5 mM MgCl2.
37 No line broadening was
observed, and the obtained structure closely resembled their previously re-
ported apo-daptomycin structure.42
Ball et al. also reported the structure of Ca2+-bound daptomycin using an
0.8 mM solution of daptomycin at pH 5.3.36 There were no major differences
between their Ca2+-daptomycin structure and their apo-daptomycin struc-
ture.
7.3. Structure of daptomycin bound to phospholipid micelles
The Straus group has reported the structure of daptomycin in 1,2-dihex-
anoyl-sn-glycero-3-phosphocholine (DHPC) micelles in the presence of cal-
cium,47 which resembled the apo-daptomycin structure. Therefore, it was as-
sumed that daptomycin experiences only a minor conformational rearrange-
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ment upon binding to DHPC micelles in the presence of Ca2+. It should be
noted, however, that with respect to both geometry and lipid composition,
such micelles are likely not a very accurate model for susceptible lipid bilayers
(see section 10.1).
7.4. Structure of tsushimycin
The solid state structure of daptomycin has not been reported. However,
the crystal structure of another cyclic lipopeptide antibiotic, tsushimycin (Fig-
ure 1), has been determined at 1.0 Å resolution.46 The peptide backbone re-
sembles a saddle with a long tail. A Ca2+ ion is bound in the middle of the sad-
dle by interaction with the side-chains of two Asp groups (Asp(1) and Asp(5)),
four backbone carbonyl O atoms (Dab(2), Gly(6), Gly(8) and Val(10)), and a water
molecule (see Figure 4A).
The peptide forms a dimer whose subunits are linked reciprocally via hy-
drogen bonds between the side chain carboxyl group of Asp(7) of one molecule
and side chain amino group and amide N-H of Dab(9) of the other. The car-
boxyl groups of Asp(7) and Asp(1) in one molecule of the dimer interacts with
an additional Ca2+ ion that lies on the surface. The side chain and carbonyl
group of Dab(9) of the other molecule interact with a water molecule that also
binds to the peripheral Ca2+. The dimers are also connected by an interaction
between the peripheral Ca2+ and the carboxyl groups of mAsp(4). There is a
tunnel through the centre of the dimer, which is large enough to accommo-
date a phospholipid molecule. Hydrophobic residues together with the fatty
acyl chains surround a cavity, while the charged groups of the molecules point
outside, resulting in a polar surface.
None of the daptomycin NMR structures are similar to the solid state struc-
ture of tsushimycin.11 Nevertheless, Asp(1) and Asp(5) in tsushimycin, which
participate in the binding of the central Ca2+ ion, are conserved in Dap, in
which they correspond to Asp(3) and Asp(7), respectively. However, studies with
a daptomycin analog having D-Asn at positions 2 and 3 and Glu at position 12
suggest that Asp(3) may not be highly important for Dap’s antibacterial activity
(see section 8). Moreover, it has been pointed out that Dab(9) in tsushimycin,
which is important for dimer formation, corresponds to Ser(11) in Dap, which
agrees with the observation that the biologically relevant species of dapto-
mycin is not a dimer (see section 10.7).
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7.5. Conclusions from NMR structural studies on Dap
The above NMR studies suggest that apo-daptomycin in aqueous solution
is highly mobile as evidenced by the fact that three groups arrived at different
structures for apo-daptomycin. Although the daptomycin structures obtained
by the different groups differed in detail, they also showed broad conforma-
tional similarities highlighting the amphipathic nature of the molecule. More-
over, daptomycin does not appear to undergo a large conformation change
upon binding Ca2+ or upon binding to DHPC micelles in the presence of Ca2+.
While the available structures may be useful for developing testable hypothe-
ses concerning structure-activity relationships, they do not capture the con-
formational change that occurs when daptomycin interacts with susceptible
target membranes.
8. Structure-activity relationships
In order to understand the action mode of daptomycin, detailed structure-
activity relationship (SAR) studies would be of great value. However, for the
most part, this work still remains to be done.
8.1. Calcium binding sites
Daptomycin in solution binds calcium stoichiometrically (section 7.2),
whereas membrane-bound daptomycin binds two equivalents of calcium (see
section 10.8). Neither of the two binding sites has been experimentally iden-
tified. It has been observed that daptomycin and all other Ca2+-dependent
cyclic lipopeptide antibiotics contain a DXDG or EF-hand motif,10 which
mediates calcium binding in calmodulin and related proteins.48 Moreover, re-
placement of either aspartate residue in this motif with alanine or asparagine
abolishes antimicrobial activity.49,50 However, in tsushimycin, only one of
these two aspartate residues participates directly in coordinating the centrally
bound Ca2+ ion, and in the available structures of daptomycin it is not obvious
how they might cooperate in Ca2+ binding (see Figure 4). Also note that, in
daptomycin and A54145, the “X” position between the two aspartate residues
is taken by a D-amino acid, which would likely alter the affinity for calcium.
NMR experiments as well as analogue studies suggest that Kyn(13) and
mGlu(12) may also be involved in binding to Ca2+ (see section 8.3).
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8.2. Role of the fatty acyl tail
In early studies it was noted that the lipid tail was essential for biological ac-
tivity. Removal of the lipid results in complete loss of biological activity, as did
the hydrolysis of the ring-closing ester bond.23 Semisynthetic n-acyl variants
showed antimicrobial activity increasing with the length of the acyl chain up to
ten carbons. Beyond this length, in vitro activity increased with some, but not
other bacterial strains; in vivo activity showed no further improvement.26 In a
planar lipid bilayer model, conductance increased with acyl chain length from
decanoyl to dodecanoyl and tridecanoyl residues. Insertion of phenylalanine
or similar residues between the fatty acyl group and the N-terminal tryptophan
caused only minor effects on activity.26 Replacement of the decanoyl residue
with pyrene- or perylene-butanoic acid—performed for the sake of fluores-
cence studies, see section 10.1—caused only minor reduction in antimicrobial
activity.51 Overall, it appears that the specific structure of the fatty acyl residue
is less important than its overall hydrophobicity.
8.3. Functional effects of single or combined amino acid substitutions
Although biosynthetic, chemoenzymatic, and total chemical synthesis
methodologies have been developed that allow for specific amino acid sub-
stitutions to be made in Dap, only a fairly limited number of analogues have
been prepared using these methodologies and examined for biological activity,
and not all of the amino acid positions have been explored (see Table 2).
Marahiel and co-workers developed a chemoenzymatic approach, in
which synthetic linear peptide precursors are circularized using a recombi-
nantly expressed thioesterase enzyme. Using this method, they prepared nine
daptomycin analogues and examined their in vitro biological activity (against
B. subtilis PY79).50 At the time of this report, it was not known that daptomycin
contains D-Asn rather than L-Asn at position 2; this was discovered only a short
time afterwards.24 Moreover, in all of their analogues, mGlu was replaced with
Glu. Consequently, most of their analogues were triple mutants containing
Glu in place of mGlu(12), the unintended L-Asn(2) substitution, as well as an
additional substitution of interest at a third position within the peptide. Since
it has been shown that the L-Asn(2) analogue24 is 10-fold, and the Glu(12) ana-
logue33 12-fold less active than native daptomycin, their results should be
interpreted with caution with respect to the effect of specific single amino
acid substitutions. Nevertheless, some important information was obtained
from these studies, namely that Asp residues 7 and 9 appear to be essential for
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biological activity, as the L-Asn(2)/Glu(12)/Asn(7) and L-Asn(2)/Glu(12)/Asn(9) ana-
logues were inactive.50 Since the L-Asn(2)/Glu(12)/Asn(3) and the L-Asn(2)/Glu(12)
analogues were 26- and 7-fold less active than daptomycin, respectively, it
appears that Asp(3) and mGlu(12) are important but not essential for activity.
Nguyen et al. have prepared nine daptomycin analogues using engineered
hybrid synthetases to substitute one or several amino acid residues in A54145,
mostly using the homologous residues from daptomycin or CDA. The hybrid
lipopeptides were tested for activity against S. aureus 33 in the absence or pres-
ence of lung surfactant. They found that Trp or Ile can replace Kyn(13) with only
a 2 and 4-fold loss of activity, respectively. D-Asn(11) can be replaced with D-
Ala or D-Ser, and D-Ala(8) with D-Ser, with remarkably little effect on biological
activity. In contrast, replacing D-Ala(8) with D-Asn causes a 12-fold decrease
in activity. Generally, most reciprocal exchanges between daptomycin and
A54145 had only minor effects on activity.
Several analogues of daptomycin have recently been prepared by total
chemical synthesis and examined for biological activity against B. subtilis.49,52
Replacing Kyn(13) with Tyr, or (2S,3R)-MeGlu(12) with (2S,3S)-MeGlu or Thr(4)
with Ser resulted in a 35 to 60-fold loss of activity at 5 mM Ca2+. Interestingly,
at increased calcium concentrations, the activity of these peptides increased
greatly and approached that of native daptomycin, which suggests that these
modifications mainly affect Ca2+ affinity but might have little effect on other as-
pects of daptomycin’s action mechanism. A Glu(12)/Trp(13) analogue exhibited
activity approaching that of daptomycin.49 In contrast, an Ala(7)/Glu(12)/Trp(13)
analogue was completely inactive even at very high Ca2+ concentration, which
is consistent with Asp(7) being crucial for Ca2+ interactions and Dap’s activity.52
Martin et al. reported the total chemical synthesis of two daptomycin
analogues and their enantiomers and evaluated their activity against S. au-
reus.54 In both analogues, mGlu(12) was replaced with Glu and Thr(4) with
L-diaminopropionic acid, thus replacing the ring-closing ester linkage with an
amide linkage. In one of the analogues, a third substitution was introduced
(Kyn(13) was replaced with Trp). These two analogues were 100 to 200-fold less
active than daptomycin, which illustrates the importance of the ester bond to
biological activity. Interestingly, the enantiomers were completely devoid of
activity, indicating that a specific chiral interaction is required for activity.
Using a semi-synthetic approach to analogue synthesis, He et al. have
shown that Trp(1) can be replaced with a surprisingly wide variety of unnat-
ural aromatic amino acids and still retain good activity against S. aureus.55 In
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Table 2: Antibacterial activities of daptomycin analogues with single or multiple amino acid
substitutions. Ellipses indicate residues that are retained from native daptomycin.
Peptidea Amino acid position MIC ratiob
1 2 3 4 5 6 7 8 9 10 11 12 13
Dap Trp D-Asn Asp Thr Gly Orn Asp D-Ala Asp Gly D-Ser mGlu Kyn 1
1 24 . . . L-Asn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2 50 . . . L-Asn Asn . . . . . . . . . . . . . . . . . . . . . . . . Glu . . . 27
3 50 . . . L-Asn . . . . . . . . . . . . Asn . . . . . . . . . . . . Glu . . . ∞e
4 50 . . . L-Asn . . . . . . . . . . . . . . . . . . Asn . . . . . . Glu . . . ∞e
5 50 . . . L-Asn . . . . . . . . . . . . . . . . . . . . . . . . . . . Gln . . . 10
6 50 . . . L-Asn . . . . . . . . . . . . . . . . . . . . . . . . D-Asp Glu . . . >100
7 50 . . . L-Asn . . . . . . . . . . . . . . . . . . . . . . . . . . . Glu Trp 33
8 50 . . . L-Asn . . . . . . . . . Lys . . . . . . . . . . . . . . . Glu Trp 33
9 33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Trp 2
10 33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ile 4
11 33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Val 8
12 33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Glu . . . 16
13 33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-Ala . . . . . . 2
14 33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-Asn . . . . . . 2
15 33 . . . . . . . . . . . . . . . . . . . . . D-Lys . . . . . . D-Asn . . . . . . 2
16 53 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-Asn Glu . . . 64
17 53 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D-Asn . . . Ile 8
18 53 . . . . . . . . . . . . . . . . . . . . . D-Asn . . . . . . . . . . . . . . . 16
19 53 . . . . . . . . . . . . . . . . . . . . . D-Asn . . . . . . . . . Glu . . . 256
20 53 . . . . . . . . . . . . . . . . . . . . . D-Asn . . . . . . . . . . . . Ile 32
21 33 . . . . . . . . . . . . . . . . . . . . . D-Ser . . . . . . . . . . . . . . . 2
22 49,52 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . mGluc . . . 40-50
23 52 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tyr 47
24 49,52 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Glu Trp 2-5
25 49 . . . . . . . . . Ser . . . . . . . . . . . . . . . . . . . . . Glu Trp >100
26 49 . . . . . . . . . . . . . . . . . . Ala . . . . . . . . . . . . Glu Trp ∞e
27 54 . . . . . . . . . Dapad . . . . . . . . . . . . . . . . . . . . . Glu . . . 200
28 54 . . . . . . . . . Dapad . . . . . . . . . . . . . . . . . . . . . Glu Trp 100
29 55 Phe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
30 55 Tyr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . >32
a numbered citations refer to the main reference list at the end of the article
b MIC of analog/MIC of daptomycin
c this analogue contained (2S,3S)-3-methylglutamate, i.e. the diastereomer of the native amino acid residue
d Dapa = L-diaminopropionic acid
e ∞ indicates complete loss of activity
contrast to Dap, some of these analogues were also active in the presence of
lung surfactant.
Many daptomycin analogues have been made by modification of the Orn(6)
amino group.56,57 The amino group was found not to be essential for antibac-
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terial activity as many of these analogues retained good biological activity
though retention of at least one NH proton in the derivatized Orn side-chain
was important for retaining potency. The role of the amino group in the mode
of action is unknown.
9. Cellular sites of action
The bacterial cell membrane was recognized early on as the major target
site of daptomycin. In 1987, Allen et al. reported that daptomycin, in a calcium-
dependent manner, caused K+ leakage from Staphylococcus aureus cells.58 Cell
fractionation experiments detected daptomycin bound to cell walls and cell
membranes, but not to cytosolic constituents.59 The latter study also reported
that daptomycin inhibits the biosynthesis of cell wall macromolecules, and
the authors proposed inhibition of lipoteichoic acid biosynthesis as dapto-
mycin’s major mode of action. Several studies have attempted to determine
whether daptomycin indeed directly blocks some enzyme or substrate in cell
wall biosynthesis, or alternatively, inhibition of macromolecular synthesis oc-
curs downstream of membrane permeabilization and loss of key metabolites;
this question remains controversial (see section 11).
Sublethal concentrations of daptomycin were found to cause elongation of
bacterial cells, which suggested that daptomycin interferes with cell division.59
This observation has been substantiated and extended in subsequent studies
(see section 10.10).
10. Interactions withmembranes
Daptomycin’s effect on bacterial membranes has been the subject of nu-
merous studies with both cells and model membranes. The findings of these
studies largely complement each other, but some of the effects observed with
model membranes are probably of limited significance in vivo.
10.1. Lipid specificity
Early studies with model membranes used mostly phosphatidylcholine
(PC) membranes, sometimes supplemented with cholesterol.38,60 Daptomycin
bound to such membranes in a calcium-dependent manner, as evidenced by
an increase in quantum yield and a spectral blue shift in the fluorescence emis-
sion of Kyn(13),38,61 and it also permeabilized them, as detected using planar
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Figure 5: Major phospholipids of Gram-positive bacteria. Phosphatidylethanolamine (PE) is
the major neutral phospholipid, whereas phosphatidylglycerol (PG) and cardiolipin (CL) are
acidic; with CL, only one of the phosphate groups is usually deprotonated. Lysyl-PG carries
a net positive charge. While the figure shows the myristoyl variants of all lipids, the fatty acyl
residues in vivo are subject to variation in length and degree of unsaturation.
bilayer conductivity.60 Membranes of such lipid composition are convention-
ally used as models for animal cell membranes; they are not, however, very
similar to typical bacterial cytoplasmic membranes, which are richer in acidic
phospholipids. Since daptomycin is selective for bacterial membranes, the
question arose what role acidic lipids might have in its activity. The two acidic
phospholipids phosphatidylglycerol and cardiolipin (Figure 5) are abundant
in bacterial membranes,62 and as it turns out, both affect the function of dap-
tomycin. At least some of these effects can be observed both with bacterial
cells and with model membranes.
CD spectroscopy indicates that even in the presence of Ca2+ daptomycin
undergoes only a minor, if any, conformational transition when binding to
pure PC membranes; however, the conformation changes profoundly on mem-
branes containing both PC and PG.42 Inclusion of PG in model membranes
also significantly enhances the fluorescence quantum yield of Kyn(13), suggest-
ing that this residue becomes more deeply buried in the lipid bilayer.42 The
conformational change induced by PG was ascribed to a bridging interaction
20
between it and one of the acidic residues in daptomycin,42 and it may be cor-
related to the formation of daptomycin oligomers, which also depends on the
presence of PG in the membrane (see section 10.7).
The evidence regarding the stoichiometric ratio of daptomycin to PG is
somewhat conflicting. Fluorescence studies using perylene-labelled dapto-
mycin and a lipid bicelle system consisting of DMPC, DMPG, and dihexanoyl-
PC produced a maximal perylene excimer signal at an equimolar ratio of pep-
tide and PG, suggesting that the interaction is stoichiometric.51 In contrast,
isothermal titration calorimetry (ITC) using daptomycin and DOPC/DOPG
liposomes suggests that each daptomycin molecule binds two molecules of
PG.63 One possible explanation for the discrepancy is that the lipopeptide
molecules interact with both leaflets of the bicelle but with only the outer
leaflet of the liposome. Alternatively, the fluorescence assay and ITC might
report on different stages of daptomycin’s membrane interaction that require
only one and two molecules of PG, respectively. In either case, a defined sto-
ichiometric ratio suggests that PG interacts with daptomycin directly, rather
than only indirectly through influencing bulk properties of the membrane
such as lateral phase or charge segregation.
A key role of PG in the action mechanism of daptomycin is also supported
by observations with bacterial cells. Fluorescently labelled daptomycin prefer-
entially binds to PG-enriched membrane domains in Bacillus subtilis cells.64
Susceptible bacterial species such as Staphylococcus aureus contain large
amounts of PG in the cytoplasmic membrane, and mutations that reduce
its abundance are associated with decreased susceptibility (see section 12).
Interestingly, Streptomyces species, which are Gram-positive organisms and
therefore should in principle be susceptible to daptomycin, generally contain
very little PG.65 It seems possible that this trait lets Streptomyces roseosporus,
daptomycin’s producer organism, avoid the bactericidal effect of its own poi-
son, although no experimental data seem to be available on the PG content of
this particular species.
While cardiolipin has been implicated in interactions with daptomycin by
several lines of evidence, its role in the action mechanism is less well-defined,
and its net effect on daptomycin activity is less certain. Inclusion of 10% CL
in model membranes causes more avid membrane binding of daptomycin, as
evidenced by both ITC and monolayer compression experiments.66 However,
in the liposome model at least, CL inhibits membrane permeabilization,66
which suggests that it might mediate resistance to daptomycin by competing
for it with PG. Such an effect has indeed been claimed to occur in vivo,67 but
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the CL-enriched membrane domains purported in that study were identified
by staining with nonyl-acridine orange, which has since been shown to bind
to phosphatidylglycerol also.68 Thus, no conclusive evidence is available to
support a preferential interaction between daptomycin and CL in vivo (see
also section 12).
Since phosphatidylglycerol is rare in mammalian cell membranes, dapto-
mycin’s requirement for this lipid may explain its low toxicity for humans. How-
ever, the interaction of daptomycin with mammalian membrane constituents
has not been systematically studied. Interestingly, the lipid composition of
lung surfactant differs significantly from that of cell membranes. While di-
palmitoyl-PC is the most prominent constituent, PG contributes up to 10%
of the total lipid in lung surfactant.69 This relatively high PG content may be
involved in the inhibition of daptomycin by surfactant (see section 3).
10.2. Role of bacterial proteins in daptomycin membrane binding
Boaretti and Canepari used affinity chromatography to isolate daptomycin-
binding proteins from Enterococcus hirae cell membranes.70,71 Binding of the
proteins to immobilized daptomycin was Ca2+-dependent, but EDTA failed
to elute the bound proteins. While this behaviour appears surprising, it does
resemble the binding of daptomycin to intact membranes, as observed in the
same studies.
The authors propose that the isolated proteins are related to lipoteichoic
acid biosynthesis, disruption of which they maintain to be the major action
mechanism of daptomycin. However, the amino acid sequences of these pro-
teins were not determined, nor have their biochemical activities been char-
acterized. While potentially of great significance, their actual relevance to
daptomycin’s action mechanism therefore remains unknown.
10.3. Distribution of cell-bound daptomycin
In Bacillus subtilis, fluorescently labelled daptomycin (BODIPY-Dap; Fig-
ure 3) binds preferentially to division septa and in forespore membranes.64,72
The remainder of the cell surface is non-uniformly labelled, in a pattern that
has been described as spiral-shaped64 or patchy.72 Daptomycin-rich mem-
brane areas also bind labelled vancomycin and penicillin derivatives, suggest-
ing that daptomycin, too, may bind to one of the substrates or enzymes in-
volved in peptidoglycan synthesis.72 An alternative interpretation is based on
membrane curvature; daptomycin is proposed to prefer “negative curvature,”
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or concave membrane surfaces in the case of the septum, and “positive cur-
vature,” or convex surfaces, in case of the forespore membrane.72 It should
be noted, however, that in the latter study it was not ascertained how the
bound daptomycin was distributed between the inner and the outer mem-
brane leaflets. The outer leaflet is concave where the inner one is convex, and
vice versa; therefore, any curvature preference that daptomycin may have can-
not be diagnosed with certainty from the reported findings.
The daptomycin-enriched membrane areas, in particular the septum, were
also found to attract DivIVA,72 a protein involved in the control of cell division,
which may link daptomycin binding to the aberrant cell division and morphol-
ogy that has been observed in several studies (section 10.10).
10.4. Membrane depolarization
Using a K+-selective electrode, Allen et al demonstrated that daptomycin
promoted the loss of intracellular K+ from Staphylococcus aureus cells imme-
diately after exposure to the drug and calcium.58 Similarly, Silverman et al.
employed a K+-sensitive fluorescent probe to demonstrate that 5 µg/ml dap-
tomycin can trigger K+ release from S. aureus suspended in Hepes buffer (pH
7.2).73 K+ release is accompanied by a collapse of membrane potential, as ev-
idenced by the release of the membrane-permeant cation tetraphenylphos-
phonium; in contrast, the transmembrane pH gradient remains unaffected, as
shown by the unaltered cellular accumulation of acetylsalicylic acid (ASA), a
weak acid organic acid whose protonated form equilibrates across the mem-
brane.74 Daptomycin inhibits the cellular uptake of amino acids by active trans-
port, which depends on the membrane potential.75
Since the potassium concentration is higher inside the cell than outside, a
K+-selective membrane permeabilization (as is induced by the ionophore vali-
nomycin for example) would hyperpolarize rather than depolarize the mem-
brane. The fact that daptomycin causes depolarization suggests that perme-
abilization is in fact not K+-selective. This is borne out by in vitro experiments
with liposomes (see section 10.5).
10.5. Functional size and solute specificity of the membrane defect
Several lines of evidence indicate that daptomycin does not induce large de-
fects in the cell membrane. Studies using both scanning electron microscopy
(SEM) and transmission electron microscopy (TEM) indicate that daptomycin
does not cause cell lysis of S. aureus and E. faecalis, although some morpho-
logical changes are observed.76,77 With Staphylococcus aureus in liquid culture,
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daptomycin at 4 µg/ml produced a 103-fold decrease in cell viability with no
concomitant drop in optical density.76 Electron microscopy showed that the
cells remained intact, and the cell membranes free of discontinuities, but for-
mation of aberrant division septa was common. When the cells were loaded
with calcein, an anionic fluorescent small molecule, the dye was retained after
exposure to daptomycin even after the cells had lost viability. Similarly, the
nucleic acid stain TO-PRO3 remained excluded by cells even after treatment
with daptomycin.76
Another nucleic acid stain whose exclusion by cell membranes is often
used as an indicator of cell viability is propidium iodide. Using this assay,
a fraction of the cells in a liquid culture of Staphylococcus epidermidis were
found to be permeabilized after daptomycin treatment.32 Such findings should
be interpreted with caution, however. Propidium is very similar in structure
to ethidium, which is widely used as a model substrate for bacterial efflux sys-
tems.78 These efflux systems are driven by ion gradients or ATP, both of which
vanish when daptomycin takes effect.79 This suggests that penetration of the
dye may measure the cell’s residual metabolic capacity for powering efflux
rather than membrane continuity. Similar considerations may apply to Sytox
Green, which like ethidium and propidium is an organic, aromatic cation with
affinity for DNA. This dye enters cells only after prolonged exposure to dapto-
mycin;72 the steep increase in DNA staining between 25 and 30 minutes under
that study’s experimental conditions is quite striking and would be surprising
if dye uptake were controlled simply by passive diffusion.
Liposome studies of membrane permeabilization have reported somewhat
divergent findings. Jung et al. reported that high concentrations of daptomycin
(30 µg/ml) caused very little calcein leakage from DOPC liposomes but 100%
calcein leakage from DOPC/DOPG liposomes.42 Surprisingly, preincubation of
daptomycin with Ca2+was required for the maximal effect. If the same concen-
trations were added separately to the calcein-loaded DOPC/DOPG liposomes,
less than 10% leakage was observed even at 16 µg/mL daptomycin. Later, this
same group, in collaboration with others, using essentially the same assay,
reported only 7% calcein release from DOPC/PG liposomes at 32 µg/mL of
daptomycin,32 which seems more in line with the previously discussed results
obtained with bacterial cells.76
Using a coupled fluorescence assay that is based on the pH-sensitive indica-
tor pyranine,80 Zhang et al. recently demonstrated that daptomycin can form
pores in DMPC/DMPG (1:1) liposomes.81 The pores are selective for cations,
with permeabilities being highest for Na+, K+, and other alkali metal ions. The
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permeability was approximately twice lower for Mg2+, and even lower for the
organic cations choline and hexamethonium. Daptomycin-induced leakage
of K+ was slow compared with that of valinomycin, a K+-specific ionophore,
at comparable concentrations. Anions were excluded, as was the zwitterion
cysteine. Such permeability properties would account for the loss of K+ and
the depolarization of bacterial cells, but also for their continued exclusion or
retention of dye molecules, particularly anionic ones such as calcein, after
exposure do daptomycin.
10.6. Depletion of substrates and metabolic energy
While there is no conclusive evidence that the daptomycin membrane le-
sion is permeable for any solutes other than small cations, daptomycin-ex-
posed cells nevertheless become depleted of ATP concomitantly with cation
loss and membrane depolarization.79 ATP regeneration by oxidative phospho-
rylation will stall when the membrane potential collapses, and moreover the
loss of cellular Mg2+, which normally stabilizes ATP, should also contribute
to ATP depletion. The depletion of amino acids due to the failure of active
uptake75 was already noted earlier (see section 10.4).
ATP depletion should disrupt macromolecular biosynthesis. Indeed, La-
ganas et al. have demonstrated that daptomycin, at twice its MIC, inhibited
all macromolecular synthesis in Staphylococcus aureus, Enterococcus faecalis,
and Enterococcus hirae.82 Similarly, Hobbs et al. found that the synthetic path-
ways for DNA, RNA, protein and peptidoglycan all become simultaneously
inhibited, and that this inhibition occurs on a similar time scale to the loss of
ATP.79
From the above observations, the question naturally arises whether mem-
brane permeabilization also controls the time course of bactericidal action.
While this question was answered in the affirmative by Silverman et al.,73
Hobbs et al. maintain that the loss of cell viability precedes that of biosynthetic
capacity. However, their reported kinetics of cell killing and biosynthetic col-
lapse differ only by some minutes.79 Moreover, since daptomycin is tightly
bound to the cell membrane,59 its effect will not be promptly terminated by
dilution, and thus the time course of its bactericidal action cannot be accu-
rately determined. Therefore, no substantial evidence contradicts the tenet
that indeed membrane permeabilization sets the pace for bactericidal action.
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10.7. Daptomycin oligomer formation
Membrane-permeabilizing peptides and proteins quite commonly form
oligomeric structures in the target membrane. Accordingly, the proposal by
Silverman et al.73 that daptomycin also forms oligomeric membrane pores or
channels was quite readily accepted, although at the time no experimental evi-
dence of oligomer formation had been obtained. More recently, Muraih et al.45
demonstrated oligomer formation on liposomes and on bacterial membrane
vesicles by FRET, using the Kyn(13) residue of unlabelled daptomycin as the
donor and an extrinsic NBD moiety attached to Orn(6) as the acceptor (NBD-
daptomycin, Figure 3). When NBD-daptomycin was used alone, oligomer
formation was also evident by self-quenching of the dye. Oligomerization
was dependent on Ca2+ and on the presence of PG in the target membranes.
Subsequently, the FRET assay was used to measure the number of subunits
contained in one daptomycin oligomer, which was found to be approximately
6-7 in DMPG/DMPC (1:1) liposomes.83
A series of experiments by Zhang et al. addressed the relevance of oligomer
formation for daptomycin’s antibacterial activity.63 These experiments used
mixtures of daptomycin and of CB-182,462, a semi-synthetic derivative of
A54145 (Figure 1). Hybrid oligomers were detected on both liposomes and on
bacterial cells using FRET and other fluorescence assays. The hybrids resem-
bled homogeneous oligomers in thermodynamic stability; they had, however,
less than additive antibacterial activity.
If each individual lipopeptide molecule contributed independently and
proportionally to the antibacterial effect, combinations of the two antibiotics
should display strictly additive activity. The observation that they inhibit each
other within hybrid oligomers indicates that the oligomer subunits are not
functionally independent; therefore, the oligomeric state is indeed relevant to
daptomycin’s antibacterial activity.
10.8. Topology of membrane-associated daptomycin
Since the membrane-associated oligomer is involved in daptomycin’s bac-
tericidal effect, a detailed model of its three-dimensional structure would be
of great value. However, no such model is as yet available; while NMR struc-
tures have been obtained for daptomycin in solution and with phosphatidyl-
choline micelles, no such studies have been reported using a suitable model of
a susceptible membrane. Therefore, all available information on the topology
derives from fluorescence studies and is of low resolution. Nevertheless, some
useful insights have been obtained concerning the distribution of daptomycin
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Figure 6: Hypothetical model of the membrane-associated daptomycin oligomer. A and B:
Top and side view of the octamer that spans both leaflets and forms a functional pore. C: A
tetrameric form that is confined to the outer leaflet has been observed on membranes con-
taining cardiolipin 66 and may also occur at sub-saturating calcium concentrations. 84
across the two membrane leaflets, the positions of individual residues relative
to the bilayer, and the mutual proximity of residues within the oligomer.
While daptomycin will initially interact with the outer membrane leaflet,
the fact that it permeabilizes the target membrane suggests that it will ulti-
mately penetrate the inner leaflet also. This question was studied using NBD-
daptomycin, which is susceptible to reduction by the membrane-impermeant
reducing agent diothionite. On susceptible (PC/PG) model membranes, only
half of the membrane-bound NBD-daptomycin was immediately reduced by
dithionite, suggesting that the remainder resided in the inner leaflet. Intrigu-
ingly, inclusion of cardiolipin in the liposomes rendered all NBD subject to
immediate reduction, suggesting that daptomycin was restricted to the outer
leaflet. Concomitantly, membrane permeabilization was inhibited, and the
number of subunits in the daptomycin oligomer was reduced to four. From
these findings, the hypothetical octameric structure shown in Figure 6 was
proposed.66
Various fluorescence studies have identified membrane-inserted residues.
The intrinsic fluorescence of Kyn(13) undergoes a strong blue-shift and in-
crease in quantum yield.38,42 The fluorescence of Trp(1) becomes protected
from quenching by iodide upon membrane binding.41 Since A54145 does not
contain kynurenine, the fluorescence of its Trp(1) residue is not attenuated by
FRET, and the stronger signal allows a clear blue-shift to be observed upon
membrane binding.85 Residues 1 and 13 are therefore membrane-inserted.
Emission blue-shifts and increased quantum yields are also observed with
the extrinsic labels NBD and acrylodan attached to Orn(6) in daptomycin and
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to Lys(8) in A54145, indicating that these residues, too, assume membrane-in-
serted positions.45,63,85
When the fluorescence of all four residues—1, 6, 8, and 13—are moni-
tored at different calcium concentrations, it turns out that the spectral changes
that signal membrane insertion occur at lower calcium concentrations with
residues 6 and 8 than with residues 1 and 13,85 suggesting that residues 6 and 8
insert in a partially Ca2+-saturated state of daptomycin, whereas residues 1 and
13 insert only at full Ca2+ saturation. This agrees with the observation by ITC
that, in the presence of PC/PG liposomes in molar excess, each daptomycin
molecule binds two Ca2+ ions.85 Concomitantly with insertion of residues 1
and 13, the fluorescence of acrylodan-labelled residues 6 and 8 decreases due
to self-quenching, indicating that these residues are involved in the interaction
between adjacent subunits in the oligomer.85
Proximity also exists between the fatty acyl tails of adjacent oligomer sub-
units. This is evident from the excimer fluorescence of perylene or pyrene
incorporated into the acyl residues of daptomycin51 and A54145,84 respec-
tively (see Figure 7). In spite of their direct attachment to Trp(1), excimer
fluorescence—and thus, aggregation of fatty acyl residues—arises already
in the partially Ca2+-saturated state,84 while Trp(1) responds only at full Ca2+
saturation. Intriguingly, global analysis of time-resolved excimer fluorescence
indicates that, even at partial Ca2+ saturation, membrane-bound A54145 al-
ready exists as an oligomer, which however has a lower number of subunits
that the one observed at full saturation.84 This observation may be related to
the proposed occurrence of daptomycin tetramers as intermediates of pore
formation (see Figure 6). In this context, it is also worth mentioning that
daptomycin may interact with membranes even in the absence of calcium, as
shown by fluorescence polarization anisotropy in an early study,38 although
this observation does not indicate oligomer formation.
10.9. Membrane fusion, flip-flop, and lipid extraction
Several studies have reported findings that are of potential interest, but
whose relevance to daptomycin’s in vivo activity is uncertain. PC/PG lipo-
somes were observed to undergo fusion when exposed to daptomycin.41 Bac-
terial cell membranes are surrounded by a cell wall that prevents fusion, and
therefore it is clear that this experimental phenomenon does not directly trans-
late to intact cells. Increased lipid flip-flop was demonstrated with a lipid ana-
logue that incorporates the somewhat polar NBD label into a shorted acyl side
chain,42 but not with a head group-labelled lipid probe.66 Both lipid analogues
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Figure 7: Structures and antimicrobial activities of perylene- and pyrene-labelled derivatives
of daptomycin and A54145, respectively. Both can be used to track oligomer formation due to
their excimer fluorescence.
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are synthetic, and thus the relevance of both of these observations to natural
bacterial membranes remains uncertain.
Very recently, Huang and co-workers have proposed a novel mechanism
for daptomycin-induced membrane damage.86 They employed fluorescence
microscopy to monitor the interaction of daptomycin with giant unilamellar
vesicles (GUVs) composed of DOPC/DOPG (7:3). The vesicles were, at the
same time, partially pulled into a tube using constant suction. Exposure to
daptomycin caused the vesicles to withdraw from the tube, indicating an in-
crease in surface tension. Some, but not all, of the video sequences published
by the authors showed that daptomycin was exuding from the vesicle mem-
branes. From this, the authors concluded that lipids were being extracted also.
However, while the extraction of lipids would indeed account for changes in
surface tension, daptomycin might well affect surface tension in other ways,
for example through changes in lipid packing and curvature strain. The au-
thors proposed that lipid extraction accounts for daptomycin’s antibacterial
activity, but they did not provide any evidence for this hypothesis, nor did they
specify how it might be substantiated experimentally.
10.10. Effects on cell division and morphology
Daptomycin’s preference for division septa (see section 10.3) suggests that
it interferes with cell division, which is also reflected in changes to the mor-
phology of daptomycin-exposed cells. Elongated forms of Enterococcus and
Bacillus cereus cells grown at MIC were reported in early studies.59 Bacillus
subtilis cells grown with daptomycin at below MIC appeared bent and elon-
gated.72 While elongated cell forms suggest that division is inhibited, the ob-
servation of additional, aberrant septa in Staphylococcus aureus 76 could mean
that cell division may be dysregulated rather than disrupted.
11. Inhibition of macromolecular synthesis
While membrane permeabilization appears to suffice for its bactericidal ef-
fect, daptomycin might nevertheless also specifically inhibit macromolecular
biosynthesis pathways. A precedent for a dual action mechanism is provided
by the lantibiotic nisin, which binds to lipid II and, like daptomycin, perme-
abilizes the membrane, but at the same time also disrupts peptidoglycan syn-
thesis.87
We noted above that daptomycin-permeabilized cells become depleted of
ions, substrates, and metabolic energy, which results in a general disruption of
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macromolecular biosynthesis also (see section 10.6). Therefore, to prove that
daptomycin directly and specifically inhibits a given biosynthetic pathway, it is
not enough to show this pathway to be obstructed in whole bacterial cells, and
we must regard as inadmissible all reported evidence of this kind. Applying
this filter leaves us with a rather manageable body of evidence, all of which is
essentially negative.
11.1. Lipoteichoic biosynthesis
Canepari et al. reported that the synthesis of lipoteichoic acid is inhibited
more readily than that of peptidoglycan in Enterococcus hirae whole cells.59
Such a preferential inhibition might arise from a requirement of LTA synthesis
for some specific metabolite or ion that is lost particularly rapidly after perme-
abilization, and therefore does not prove a direct inhibition of the pathway.
Laganas et al., who re-examined inhibition of LTA biosynthesis and other
pathways in E. hirae and other bacterial species, found no kinetic or dose
specificity for LTA.82 They also investigated the possibility that the bacterici-
dal activity of daptomycin might require ongoing LTA biosynthesis, even if it
was not the primary target. In these experiments, Staphylococcus aureus and
Enterococcus faecalis cells were treated with rifampicin, a bacteriostatic agent
which causes complete cessation of macromolecular synthesis, including that
of LTA, but does not cause significant loss in bacterial viability. The authors
reasoned that, if concurrent LTA biosynthesis were required for the action of
daptomycin, then pretreatment with rifampicin should protect bacteria from
the lethal effect of daptomycin. In contrast to this prediction, however, expo-
sure to daptomycin at eight times the MIC for 1h effectively killed S. aureus
both when exponentially growing and when growth-arrested with rifampicin.
In contrast, rifampicin did protect S. aureus against ciprofloxacin, an antibi-
otic that inhibits DNA topoisomerase and is active only on actively growing
cells.82
The findings by Laganas et al. show that LTA biosynthesis is not required for
daptomycin activity. It is also unlikely that LTA itself is a target for daptomycin,
since the antibiotic cannot be neutralized by simultaneous addition of purified
LTA even at concentrations up to 500 µg/ml.82
11.2. Peptidoglycan synthesis
The structural similarity between daptomycin and the amphomycin group
of lipopeptide antibiotics suggested early on that, like the latter, daptomycin
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might inhibit peptidoglycan biosynthesis, and this possibility continues to
attract interest.
Several early studies reported inhibitory effects on various steps in pepti-
doglycan biosynthesis;58,88,89 however, most of this evidence stems from whole
bacterial cells and thus cannot be regarded as conclusive. A cell-free assay of
peptidoglycan polymerization detected inhibition by daptomycin, but only at
concentrations that were far beyond MIC.58
A recent study employed bacterial membrane preparations to compare
the effect on LTA and peptidoglycan precursor synthesis of daptomycin, am-
phomycin, and an analogue of the latter (MX-2401).32 A strong inhibition was
seen when amphomycin and its analogue were used in twofold molar excess
over their known target bactoprenol phosphate. A twofold excess of dapto-
mycin caused an inhibition by approximately 20%. As discussed above, dap-
tomycin forms oligomers with six or more subunits (see section 10.7). If we
assume that each oligomer might neutralize no more than one or two carrier
lipid molecules, it seems possible that a greater molar excess of daptomycin
might cause a stronger inhibition. It may be worthwhile to repeat these exper-
iments under such conditions.
12. Resistancemechanisms
Clinical cases of daptomycin non-susceptibility emerging during therapy
have been documented in important pathogens such as Staphylococcus au-
reus as well as Enterococcus and Streptococcus species.3,5 Complete genome se-
quences of resistant strains have identified several mutational hot spots. While
most of the genes in question are functionally related to the cell membrane
and the cell wall,1,11 the phenotypic mechanism that links them to daptomycin
susceptibility and resistance is understood only in a few cases. More research
into the underlying bacterial physiology should also help to elucidate dapto-
mycin’s mode of action.
12.1. Reduced synthesis of PG
We had seen that PG facilitates daptomycin binding and permeabilization
of membranes (section 10.1). In bacterial cells, PG is also the biosynthetic
precursor of CL and of lysyl-PG. Accordingly, decreased biosynthesis of PG and
its increased conversion to CL or lysyl-PG may all cause changes to bacterial
susceptibility. The latter two lipids may also have their own specific effects on
daptomycin susceptibility.
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The gene pgsA encodes a CDP-diacylglycerolglycerol-3-phosphate 3-phos-
phatidyltransferase that is involved in the production of PG. Mutations that
reduce its activity reduce membrane PG levels and daptomycin susceptibility
in Bacillus subtilis and Staphylococcus aureus.64,90,91
12.2. Lysyl-phosphatidylglycerol
Lysyl-phosphatidylglycerol (lysyl-PG, see Figure 5) is a regular cell mem-
brane constituent of Gram-positive bacteria. Its is formed from PG in a trans-
esterification that uses lysyl-tRNA as a cosubstrate. The reaction is catalysed
by the membrane protein MprF, which also supplies the translocase activity
that subsequently transfers lysyl-PG from the inner to the outer membrane
leaflet.92 The abundance of lysyl-PG in bacterial membranes correlates with
resistance to both cationic antimicrobial peptides93 and daptomycin. Gain-
of-function mutations in the mprF gene cause increased lysyl-PG levels, de-
creased PG levels, and daptomycin resistance in Staphylococcus aureus (see
reference 94 and citations therein). Conversely, deletion of mprF induces hy-
persensitivity to daptomycin.95
Since both amino groups of its lysyl residue are free, lysyl-PG carries a pos-
itive net charge. Electrostatic repulsion may be involved in the protection of
bacterial cells from cationic antimicrobial peptides, and possibly also from
Ca2+-saturated daptomycin, although model studies with liposomes suggest
that the effect occurs after the peptides have become membrane-bound.96
Moreover, it has been shown that not all daptomycin-resistant isolates with
mprF mutations exhibit changes in cell surface charge.97,98 Hence, it has been
suggested that the mutations in mprF may simply be reducing the amount of
PG in the cell membrane, which would affect daptomycin’s ability to interact
with the membrane and form functional oligomers.13
12.3. Cardiolipin
In model membranes, cardiolipin promotes membrane binding of dap-
tomycin but inhibits permeabilization (section 10.1). This suggests that in-
creased synthesis of CL could mediate bacterial resistance to daptomycin. In-
deed, cardiolipin synthase mutants have been isolated from resistant mutants
of Staphylococcus aureus 91 as well Enterococcus species.99 Some of these mu-
tants have been shown to have increased activity,100 but their substitution into
the genome of a daptomycin-susceptible strain did not detectably increase
resistance.101 A study that comprehensively characterized the membrane lipid
compositions of daptomycin-resistant Staphylococcus aureus strains found
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the expected decrease in PG, as well as an increase in lysyl-PG, but no signif-
icant change in CL.94 Since CL is formed from PG, it seems possible that CL
synthase gain-of-function mutants merely compensate for the reduction in
substrate levels.
12.4. Cell wall permeability
Enhanced expression of the dlt operon has been found to occur in dap-
tomycin-resistant strains of Staphylococcus aureus.98,102–106 The dlt operon is
involved in the incorporation of D-alanine into cell wall teichoic acids. The
alanylation of these surface-exposed structures results in an increase in the
net positive charge of the cell surface, which may affect daptomycin’s abil-
ity to function in the same manner as PG lysylation. Moreover, teichoic acid
D-alanylation reduces penetration of the cell wall by cationic antimicrobial
peptides,107 a mechanism that also appears plausible with daptomycin.
12.5. Mutations in the yycFG operon
The yycFG operon is a hot spot for mutations conferring daptomycin resis-
tance. It encodes the yycFG response regulator system, which controls cell wall
metabolism and biofilm formation.108,109 in vitro -derived resistant mutants
of Staphylococcus aureus exhibited changes affecting the histidine kinase of
the system (YycG).110,111 In Bacillus subtilis, this protein is located at the cell
division septum, where it regulates cell division and wall restructuring.112
Several mutations in different locations of the yycFG operon in daptomycin-
resistant S. aureus were reported by Howden et al., although their exact con-
tribution to resistance is unclear.113 Nevertheless, a single amino acid change
in YycG was sufficient to increase the MIC from 0.5 to 2 µg/L, a value that is
sufficient for clinical resistance. In Enterococcus faecium, mutations in the
yycFG operon have also been found in daptomycin-resistant strains.101,114
Another line of evidence that connects yycG to daptomycin’s MOA has been
pointed out by Baltz.11 YycG is localized at the cell division septum, and inhibi-
tion of YycG causes aberrant cell division septa. Daptomycin binds preferen-
tially at the cell division septum and also causes the formation of aberrant cell
division septa (see section 10.10). Depletion of YycG causes rapid cell death
without lysis, as does daptomycin (section 10.5). YycFG also positively regu-
lates biofilm formation, while daptomycin treats S. aureus biofilms effectively.
Baltz has therefore proposed that, in addition to the dissipation of membrane
potential, daptomycin may also exert by directly inhibiting YycG. This hypoth-
esis has yet to be addressed experimentally.
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12.6. Activation of LiaRS
The membrane-associated transcriptional regulator LiaRS is activated by
antimicrobial peptides, as well as by antibiotics that interfere with cell wall
synthesis. It is also activated by daptomycin, which in turn reduces bacterial
daptomycin susceptibility.64,115
While LiaRS is found in all Gram-positive bacteria, interest has focused on
Enterococcus species in the context of clinical daptomycin resistance. Arias
and co-workers characterized LiaRS mutations in clinical isolates of Entero-
coccus faecalis and E. faecium that induce daptomycin resistance.116 In such
strains, the activation of LiaRS greatly reduces the efficiency of daptomycin to
bacterial cells.117
When activated, LiaRS induces the expression of LiaI and LiaH, which colo-
calize within segregated domains in the cytoplasmic membrane.118 The phe-
notypic effects of these effector molecules, and accordingly their role in dap-
tomycin resistance, are not yet understood.
13. Conclusion
From the foregoing discussion, it will be clear that daptomycin’s action
mechanism is not fully understood. While the formation of oligomeric lesions
that permeabilize and depolarize the cell membrane has been thoroughly doc-
umented and can account for the bactericidal activity, several lines of evidence
suggest that daptomycin may also directly interfere with cell division and cell
wall synthesis. A precedent for such a dual mechanism of action is provided
by the lantibiotic nisin.87,119
In addition to the mechanism of action, much work remains to be done
regarding daptomycin’s structure-activity relationships. A larger and more
diverse set of sequence variants is needed, which should be examined for an-
timicrobial activity, but also using biophysical and biochemical methods that
illuminate specific steps in the action mode of daptomycin. Such mechanistic
studies should contribute to a more detailed understanding and hopefully en-
able the rational design of improved derivatives, which could address concerns
such as emerging resistance and inhibition by lung surfactant.
Even if the above questions can be answered, daptomycin’s complex struc-
ture will make it challenging to obtain the improved variants in sufficient
amounts for therapeutic application. The most promising way forward may
consist in a dual strategy that uses total synthesis52 on a scale sufficient for in
vitro and animal studies, while the scaling up of successful variants for clinical
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testing and application would be pursued using the synthetase engineering
techniques demonstrated by Nguyen et al.33,53
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